Post-earnings recap
Reported
Tue, May 10, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 2.24% on the day, likely due to the absence of revenue figures and guidance. Investors may be cautious as the company continues to navigate its clinical programs without clear revenue expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | +20.00% |
| Revenue | N/A | N/A | N/A |
Management highlighted the positive EPS surprise as a sign of progress. They remain focused on advancing their clinical pipeline, although no revenue guidance was provided.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They emphasized ongoing efforts in their clinical programs.